During the last decade, there has been an increasing use of a placebo run-in period prior to randomization to active treatments, or placebo in randomized controlled trials aimed at establishing acute phase antidepressant drug efficacy in patients with major depression. This procedure is thought to reduce response rates to placebo treatment after randomization, thereby increasing the drug-placebo difference. Metaanalyses of 101 studies reveal that a placebo run-in does not (1) lower the placebo response KEY WORDS: Depression; Placebo; Metaanalysis; Placebo run-in; Antidepressant medication
The placebo run-in phase has become virtually stan dard practice in randomized controlled trials (RCTs) to test the efficacy of antidepressant medications in phase III and often phase IV studies. This single-blind phase usually lasts 3-14 days, followed by patients being ran domized to treatment. However, if patients show a meaningful symptomatic reduction (usually deflned as a20% to 25% improvement on a symptom rating scale), subjects are excluded from study. The implications of this practice have rarely been empirically evaluated.
The rationale, based largely on intuition, is thought to reduce placebo responders post-randomization, thereby lowering post-randomization placebo response rates, and increasing differences between placebo and active treatments. Prien and Levine (1984) also sug-rate, (2) increase the drug-placebo difference, or (3) affect the drug response rate post-randomization in either inpatients or outpatients for any antidepressant drug group. If there is a post-randomization placebo treatment cell, drug response rates are unchanged or are slightly lower than if there is no placebo treatment cell for outpatients. These results suggest that a pill placebo run in provides no advantage in acute phase efficacy trials. [Neuropsychopharmacology 11:33-43, 1994J gested that the placebo run-in might eliminate rapid remitters, thereby reducing the need for post-randomiza tion placebo control treatment in some circumstances.
The insuffi cient empirical data amassed to test these notions have not strongly supported the practice. Reim herr et al. (1989) , in a retrospective reanalysiS, discov ered that the elimination of prerandomization placebo run-in "responders" reduced the drug-placebo differ ence from 30% to 25% in outpatients with major depres sion, and surprisingly, increased the placebo treatment response rates from 13% to 16%.
Additional circumstantial data to question the value of this practice is from adult trials that have attempted to clinically characterize placebo responders. Outpa tients who "respond" during the placebo run-in tend to have longer episodes, a more chronic illness, a lower initial level of symptom severity, and are more likely nonendogenous. In comparison, patients who respond to placebo after randomization, tend to have shorter cur rent episodes and higher symptom severity at random ization (Fairchild et al. 1986; Rabkin et al. 1986 Rabkin et al. , 1987 . These flndings, albeit from different studies, hint that those who "respond" to a placebo run-in may not be isomorphic with those who ultimately respond to post randomization placebo treatment.
METHODS

Selection of Studies
This report is based on literature identmed and tabu lated for a larger review, commissioned by the Agency for Health Care Policy and Research (Depression Guide line Panel 1993). All relevant English language, peer reviewed, randomized controlled acute phase treatment trials for inpatients and outpatients with major depres sion were included (see Depression Guideline Panel in press). The search, conducted by the National Library of Medicine, used MEDLINE and Psychological Ab stracts. Key search words included generic names of all antidepressant medications. Abstracts were obtained and reviewed for all acute phase RCTs from 1975 to 1990 (except for monoamine oxidase inhibitors [MAO Is] from which literature from 1959 to 1990 was used).
Articles that met the following inclusion/exclusion criteria were selected: (1) written in English; (2) patients had major depressive or bipolar disorder; (3) the trial had to last three weeks; (4) a quantitative outcome mea sure was used; (5) a comparison was made between a known antidepressant drug and a placebo, another medication, or both; and (6) the study was blinded. A total of 141 eligible, placebo-controlled RCTs were identmed, of which 101 could be metaanalyzed.
Evidence tables were created to summarize the author's report of either the percentage of responders in each cell or the percentage of responders between cell diff erences. The numbers randomized, responding to, and completing each treatment cell were recorded (Depression Guideline Panel, in press).
Assessment of Outcome
For this report, we focused on studies providing dichot omous outcome measures. Categorical scoring was cho sen because it addresses the question most patients want to know. How likely am I to get better if I follow treatment? In addition, categorical data was required for the meta analytic procedures.
In nearly all studies, outcome was based either on the Hamilton Rating Scale for Depression (HRS-D) (Hamilton 1960) or the Oinical Global Impression (Guy 1976) . Virtually every study that used the HRS-D counted a 50% reduction in the HRS-D score as a re sponder. If the HRS-D was not reported, then a CGI response of 1 or 2 (markedly improved, or very much improved) was counted.
Determination of Success Rates
The success of a treatment may be reported in three different ways. First, an "intent-to-treat" analysis, that utilizes all patients who improved (regardless if they NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.1 remained in the study) as the numerator, and the num ber randomized to treatment as the denominator, ad dresses the question of how many patients randomized to the treatment improve. Second, an "adequate treat ment" analysis includes only patients who received a predetermined minimum amount of treatment (typi cally 2-4 weeks for medication) as the denominator, and counts those that responded as the numerator. This ap proach answers the question of how many improve from receiving at least the minimal amount of treatment thought to be effective. Finally, a "completer" analysis includes only those who completed the full protocol. The numerator and denominator include only these pa tients.
These three methods produce different responses rates. Assume that 100 patients are randomized to treat ment, 80 complete 3 weeks (defmed a priori as "ade quate treatment"), and 40 complete the treatment (e.g., 8 weeks). Assume an adequate course of treatment is 75% effective, a full course is 95% effective, and for sim plicity, patients who withdraw from treatment do not improve. Completer response rate is 0. 95 (40/40) or 95%. The adequate treatment response rate is 0. 75 (40) plus 0. 95 (40/80) or 78%. The intent-to-treat response rate is 0. 95 (40/100) or 38%. Thus, success rates range from 38% to 95% depending on the sample chosen.
We used modmed intent-to-treat analysis for this report. The denominator for this analysis was the num ber of patients randomized to each treatment cell. The numerator was the number of patients who improved while in treatment. This modmcation was required be cause very few studies followed patients after they left the trial. If some patients who left a study improved anyway (which is possible), the modihed intent-to-treat response rates will be lower than a true intent-to-treat analysis. However, the between-treatment compari sons, based on the modmed intent-to-treat analysis should generally be similar to those using a true intent to-treat analysis because response rates in subjects leav ing the study are not expected to differ across treat ments.
Method of Metaanalysis
We conducted metaanalyses using the ConfIdence Prohle Method (Eddy et al. 1990 ). This method uses a hierarchical Bayesian random-effects model and calcu lates the probability distribution that describes the results expected if a hypothetical additional study, simi lar to the ones included in the analysis, was performed. By taking into account the heterogeneity of study results, this type of analysis depicts the range of results practitioners could expect should they use the treatment in their own practice settings.
Whereas, the hierarchical random effects model is very robust, there are several potential threats to the Feighner et al. 1979; Goldberg and Finnerty 1980; Reimherr et al. 1990; Rickels and Case 1982; Rowen et al. 1982; Claghorn et al. 1983; Hormazabal et al. 1985; Irnlah 1985; Rickels et al. 1985; Amsterdam et al. 1986; Kleiser and Lehmann 1988; Spiker and Kupfer 1988 Stewart et al. 1981 , 1985 Veith et al. 1982 Jarvik et al. 1983; Rickels et al. 1985 Agnew et al. 1961 Rothman et al. 1962; Greenblatt et al. 1964; Schildkraut et al. 1964; British Medical Research Council 1965; Raskin et al. 1978; Kellams et al. 1979; Escobar et al. 1980; Feighner 1980; Gerner et al. 1980; Mann et al. 1981; Rickels et al. 1981; van der Velde 1981; Rickels et al. 1982a,b; Veith et al. 1982; Feighner et al. 1983a,b; !til et al. 1983; Jarvik et al. 1983; Meredith and Feighner 1983a; Meredith et al. 1984; Reimherr et al. 1984; Liebowitz et al. 1984a,b; Cohn and Wilcox 1985; Dominguez et al. 1985; Kocsis et al. 1985; Stark and Hardison 1985; Lipman et al. 1986; Mendels and SchIess 1986; Wakelin 1986; Lapierre et al. 1987; Rickels et al. 1987; Byerley et al. 1988; Liebowitz et al. 1988; Quitkin et al. 1988; Cohn et al. 1989; Conti and dell'Osso 1989; Elkin et al. 1989; Feighner and Boyer 1989; Kocsis et al. 1989; Lydiard et al. 1989; Peselow et al. 1989; Quitkin et al. 1989; Stewart et al. 1989; Versiani et al. 1989; Quitkin et al. 1990 White et al. 1984 Georgotas et al. 1986; Katz et al, 1990 Rickels et al. 1981 Fabre et al. 1983 Meredith and Feighner 1983b; Feighner et al. 1984; Lineberry et al. 1990 van der Velde 1981 Edwards and Goldie 1983 Kellams et al. 1979; Escobar et al. 1980; Feighner 1980; Goldberg and Finnerty 1980; Mann et al. 1981; Rickels and Case 1982; Klieser and Lehmann 1988 Reimherr et al. 1984; Cohn and Wilcox 1985; Stark and Hardison 1985; Fieve et al. 1986; Goodnick et al. 1987; Wernicke et al. 1987a; Fabre and Putnam 1987a; Byerley et al. 1988; Muijen et al. 1988; Cohn et al. 1989; Dunlop et al. 1990 Dunlop et al. " !til et al. 1983 Dominguez et al. 1985; Wakelin 1986; Lapierre et al. 1987; Conti and dell'Osso 1989; Lydiard et al. 1989 Peselow et al. 1986 Reimherr et al. 1990 Feighner and Boyer 1989; Peselow et al' 1989 Ford et al. 1959 Agnew et al. 1961; Joshi 1961; Rothman et al. 1962; Kurland et al. 1967; Davidson and Turnbull 1983; Giller et al. 1984; Davidson et al. 1988 Agnew et al. 1961 Rees and Davies 1961; Schildkraut et al. 1964; British Medical Research Council 1965; Robinson et al. 1973; Raskin et al. 1974; Ravaris et al. 1976; Rowan et al. 1982; Liebowitz et al. 1984a,b; Georgotas et al. 1986; Quitkin et al. 1988 Quitkin et al. , 1989 Quitkin et al. , 1990 Stewart et al. 1989; Georgotas et al. 1986 Bartholemew 1962 Himmelhoch et al. 1982; White et al. 1984 • Included 20 mg, 40 mg and 60 mg treatment cells. SSRIs = selective serotonin reuptake inhibitors; MAOIs = monoamine oxidase inhibitors.
internal validity of the metaanalyses. The rando m effects model accounts for among-study variations and, therefore, accounts for random bias; however, it can not account for any systematic biases that occurred in all studies. Secondly, for inclusion in the metaanaly sis, studies had to present sufficient data to permit cal culation ot the percentage ot the response tor each rrea'tment, based on the intent-to-treat sample. If studies without sufficient data were fundamentally different from those that were included, summary statistics may be biased. Similarly, a variety of publication biases (e. g. , the preferential publication of those studies disprov ing the null hypothesis) could result in biased summ ary s'tatistics. (18) 34 (27) • The numbers in parentheses are the number of trials subjected to metaanalysis.
Tabulation of Findings
We report fIndings for inpatients and outpatients separately, because attrition rates, as well as placebo and drug response rates, may differ for these two groups. We combined, however, adult and geriatric studies because (1) there is no evidence of differential responses to drug or placebo in published studies to date (Depression Guideline Panel 1993); and, (2) the number of geriatric studies was too few for meaningful independent analyses.
We divided the medications into groups. The tricy clic medications included amitriptyline, desipramine, doxepin, imipramine, nortriptyline, and protriptyline. The heterocyclic group included maprotiline, amoxa pine, trazodone, and bupropion. The selective seroto nin reuptake inhibitors (SSRIs) included fluoxetine, paroxetine, and sertraline. The MAOIs included isocar box acid, phenelzine, and tranylcypromine.
RESULTS
We posed four specifIc questions to be addressed by the metaanalyses: (1) Does a placebo run-in affect the post-randomization placebo treatment cell response rate?; (2) Does a placebo run-in affect the drug-placebo difference?; (3) Does a placebo run-in affect the drug response rate?; and, (4) Does a post-randomization placebo treatment cell affect drug response rates (with or without a placebo run-in)?
The number of studies available for intent-to-treat metaanalysis in placebo-controlled studies by individual drugs are listed in Table 1 and were as follows: for tricy-NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.1 clics, amitriptyline (n = 12), desipramine (n = 3), dox epin (n = 3), imipramine (n = 48), and nortriptyline (n = 3); for heterocyclics, amoxapine (n = 1), bupropion (n = 4), maprotiline (n = 2), and trazodone (n = 7); for the SSRIs, fluoxetine (n = 11) (with 17 cells), fluvox amine (n = 6), sertraline (n = 2), and paroxetine (n = 2); and for the MAOIs, isocarboxacid (n = 8), phenel zine (n = 16), and tranylcypromine (n = 3). Table 2 summarizes the number of studies with and without a placebo run-in by patient status used in the meta analysis. Table 3 reveals that whether or not there is a placebo run-in, post-randomization placebo treatment cell re sponse rates are identical. For example, the placebo treatment cell response rate for outpatients with a run-in was 27.8% ± 11. 0% (39 studies), compared to 28. 5% ± 8. 5% (33 studies) without a run-in. These two rates are not different from each other. The placebo treatment cell response rates for inpatients were also not differ ent between studies with and without a placebo run-in. Of additional note is the apparent fact that the placebo treatment cell response rates were similar for inpatients and outpatients. Thus, a placebo run-in does not affect the placebo cell response rates. Table 4 addresses the question of whether or not a placebo run-in affects drug-placebo differences fol lowing randomization. For outpatients, the drug-pla cebo diff erence for tricyclics was 18. 4% ± S.9% (32 studies) with a placebo run-in, compared to 21.S% ± 8. 3% (21 studies) without a run-in. Similarly for hetero cyclics, it was 20. 7% ± 18.9% (3 studies) with a placebo run-in and 14.8% ± 13. 4% (S studies) without a run-in. For the SSRIs, the drug-placebo difference with a placebo run-in was 20. 8% ± 8.S% (23 studies) versus 27.0% ± 24.2% (2 studies) without a run-in. Finally, for the MAOIs with a placebo run-in, the difference in probability for drug-placebo was 31. 1% ± 18.S% (6 studies) versus 29. 9% ± 17. 3% (8 studies) without a run-in. None of these drug-placebo differences in out patients for individual drugs with and without a placebo run-in were different from each other. The total drug placebo diff erence in outpatients for all drugs was 20.6% ± 6.2% (64 studies) with a placebo run-in versus 21. 8% ± 7. 7% (36 studies) without a run-in.
For inpatients, the drug-placebo difference for tricyclics was 25.6% ± 12.5% (8 studies) with a placebo run-in compared to 33. 1% ± 7. 9% (6 studies) without a run-in. For heterocyclics with a placebo run-in, the drug-placebo difference was 32.2% ± 13. 5% (4 studies) compared to 44. 9% ± 10.8% (3 studies) without a run in. This ftnding indicates a tendency toward a higher drug-placebo difference in heterocyclics without a placebo run-in. Similar comparisons were not possible for SSRIs versus MAOIs because there were no inpa ti ent studies of MAOIs with a placebo run-in, and no studies of SSRIs without a placebo run-in. Again, the total drug-placebo difference for all studies with a placebo run-in was 28. 5% ± 10.3% (14 studies) versus 35.6% ± 7. 7% (18 studies). In summary, Table 4 also reveals that the drug-placebo difference is only in the range of 21 % to 35%, although the drug-placebo diff er ences are consistently higher for inpatients than for out patients. A placebo run-in does not affect drug-placebo diff erences in outpatients. For inpatients, a placebo run in may actually reduce the drug-placebo difference. Table 5 addresses the question of whether a placebo run-in affects the post-randomization drug cell response rates. The drug response rates for outpatients in studies with a placebo run-in are not different from drug re sponse rates in studies without a placebo run-in. That is, the presence or absence of a placebo run-in does not affect drug response rates. This ftnding also appears to apply to inpatients.
Finally, Table 6 addresses the question of whether the presence of a post-randomization placebo treatment cell affects the drug cell response rates. For these anal yses, all relevant studies were included whether or not they had a placebo run-in. For outpatients across all medication classes except the SSRIs, the drug response rate is unaffected by whether or not there is a post randomization placebo treatment cell. Thus, the efficacy rates found in placebo-controlled trials would likely ap pear to generalize to trials without a placebo arm. For the SSRIs, however, it appears that when there was a placebo treatment arm, the drug response rate was lower than when there was no arm. With the inpatient studies, for each medication group, the presence or ab sence of a placebo treatment arm generally did not affect the drug response rate, except for the MAOIs, in which case, the inclusion of a placebo treatment arm was as sociated with a better overall response than when there was no such arm.
Thus, with few exceptions, the presence of a post randomization placebo treatment cell does not appear to affect drug response rates. For the SSRIs, this ftnding 
DISCUSSION
In summary, the previous metaanalyses provide a somewhat surprising, but relatively solid set of findings.
A placebo run-in, as compared to no placebo run-in, does not reduce (or increase) the post-randomization placebo response rate, drug response rate, or drug placebo differences. One can ask, however, about the certainty of these fIndings. The metaanalyses used are based on a substantial number of studies. The certainty of the percent response rates is reflected in the stan dard deviations; thus, for the vast majority of analy ses, the fIndings are robust. We tested the stability of these fIndings using com puter modeling for one part of the analysis. Table 3 shows that the placebo treatment cell response rate is 27.8% (± 11.0%) for 39 studies of outpatients with a placebo run-in, and 28.5% (±8.5%) for 33 studies with out a placebo run-in. In order to create a post-randomi zation placebo treatment cell response rate of 24.6% (± 11.2%) in RCTs with a placebo run-in (i.e., 3.2% lower than the 27.8% estimated in the current 39 studies), an additional 39 similarly sized studies are needed that have a placebo response rate of only 20.0% (± 10.9%).
Why might a placebo run-in generally fail to affect placebo response rates or drug-placebo differences post randomization? First, studies without a placebo run-in rarely enter patients immediately at the fIrst visit. There is often a screening visit at which informed consent is obtained, and ratings, and laboratory screening tests are conducted. Patients, even on no medication, return 3 days to 10 days later, learn that their laboratory tests are normal, receive another severity rating, and are ran domized. Sometimes a third visit, spaced only a few days after the screen visit, is needed. For example, pa tients on medications are discontinued, which may re quire an additional one to two visits. A nearly identical procedure is followed when there is a placebo run-in, as the pill placebo may be given between screen (fIrst visit) and baseline (time of randomization). Further more, the intensity and!or nature of patient educa tion! adherence counseling has generally increased over the years with or without a placebo run-in.
It is entirely reasonable to assume that the process of consenting, being educated, being screened for eligi bility, and the subsequent post-screen visits even with out a pill placebo are just as effective as a pill placebo in identifying placebo run-in "responders." That is, the pill placebo may add little except cost in identifying run-in "responders."
The fIndings in Table 4 deserve comment. There appears to be a slight difference between the effects of a placebo run-in versus no run-in on drug-placebo differences found with inpatients as opposed to out patients. For inpatients, there is a tendency for studies without a run-in to be associated with a somewhat higher drug-placebo difference; however, the number of studies in each drug group is modest, so caution is warranted. On the other hand, one might speculate that for inpatients, the lack of a placebo run-in may induce investigators to enroll more acutely (severely) ill sub-jects who in turn more specibcally benefIt from drug as opposed to placebo, thereby increasing drug-placebo differences.
In outpatients, the presence or absence of a placebo run-in generally appears to make no difference. With SSRIs, a 27.0% drug-placebo difference without a run in, versus a 20.8% difference with a run-in is not meaningful given the high standard deviations and the availability of only two studies in the former group, al though the difference is consistent with Reimherr et al. (1984) .
Secondly, in outpatients, the metaanalyses suggest that the presence of a post-randomization placebo treat ment arm generally does not signifIcantly affect drug response rates, except for the SSRIs, in which case, the absence of a placebo arm is associated with a slight in crease in the response rate. This fInding could result from patients with greater Axis II or more chronic depressions who would decline a placebo-controlled study versus entering studies without a placebo arm, if the SSRIs were particularly benefIcial for this patient group as compared to the other antidepressant classes. The latter notion is supported by Reimherr and col leagues (1984) .
The overall slightly greater drug response rates in outpatients for all drugs (Table 6 ) in trials without,op posed to those with, a post-randomization placebo treatment cell, that are not robust, are seemingly con sistent. This tendency could result from subject selec tion (i.e., less severely or chronically ill subjects being more likely included in post-marketing, nonplacebo controlled trials). Alternatively, it could result from in vestigator and participant knowledge of the lack of a placebo treatment cell, that leads to both expecting a greater response, thereby slightly inflating ratings in trials without a placebo arm, or conversely, slightly un derestimating responses in placebo-controlled trials. However, because a similar pattern is not seen with in patient trials, the case for patient/investigator bias is not strong.
For inpatients, the MAOIs with a placebo treatment cell were associated with greater efficacy than MAOIs without a placebo cell. This fInding is consistent with the notions that MAOIs may be more effective in the less severely ill (e.g., outpatients versus inpatients) (Depression Guideline Panel 1993, pp. 50-51) , com bined with the idea that less severely ill inpatients may be more likely to agree to a placebo-controlled trial than the more severely ill may agree to.
Whether or not patients who drop their HRS-D score by a predetermined degree or percent should be excluded (whether with or without a placebo run-in) cannot be addressed by this report. Logic, clinical prac tice, and the need for clinical relevance and generaliza bility would argue that if there are sufficient symptoms at randomization to indicate drug treatment, the paPlacebo Run-in for Antidepressant Trials 39 tient should be entered. That is, the raw HRS-D score at the time of randomization would seem to be the pri mary variable to dictate inclusion or exclusion. In addi tion, prior reports are consistent with the notion that patients who "respond" to a one-week placebo run-in are clinically dissimilar to those who respond to a mul tiweek post-randomization placebo treatment arm (Rab kin et al. 1987) . Reimherr and coworkers (1989) suggest that the percent drop rule may not be valid and may even slightly reduce drug-placebo differences.
Finally, measurement itself may present a problem in some patients. For example, if a patient initially scores a 22 on the HRS-D, but at randomization drops to 17, a 20% drop has occurred, and the patient is excluded. However, the reliability even of the 17-item HRS-D is on the order of ± 2 in this range. Thus, a 22 is really a score of between 20 and 24. A 17 is really a score of between 15 and 19. Thus, at least in some patients, a clinically meaningless "drop" can lead to subject ex clusion.
Conversely, Quitkin and coworkers (personal com munication, June 1994) found in a retrospective analy sis combining several trials that those with minimal severity reductions in the prerandomization pill-pla cebo run-in, had a higher response rate to either placebo or drug than those with a greater drop (although pa tients with a clinically signibcant drop were excluded). However, the drug-placebo differences in these two groups may not actually change.
From the clinical perspective, there are several reas suring fIndings that include: (1) drug response rates with or without a placebo run-in are the same, (2) whether or not there is a placebo treatment arm, seems not to affect drug response (except a better response may be present for SSRIs) when there is no such arm, and (3) the drug class involved does not change the above fIndings. To estimate effects in the "real world" of clinical practice (effectiveness) from RCTs with/with out placebo run-ins or placebo cells, these data suggest that these design features do not profoundly affect over all efficacy. That is, if practitioners follow the other procedures (e.g., weekly visits, measuring outcome, dose adjustments), an equal or better outcome for simi lar kinds of patients treated with the medication in ques tion can be anticipated.
From a research perspective, however, these fInd ings raise serious questions as to the value of a single blind pill placebo run-in to exclude patients in efficacy trials. As with any retrospective analysis, especially when combining many studies, one cannot be com pletely convinced of these results. The only sure test would be an RCT in which half the patients received a single-blind placebo run-in, whereas the other half did not. This type of study would determine if these two different procedures, each designed to exclude patients under different conditions, would perform equally, excluding the same types and numbers of subjects.
In summary, these findings lend no support to the need for a pill placebo run-in, as compared to a multi visit run-in without a pill placebo. Further, empirical studies of the utility of the percent drop rule often used during the run-in period are needed. 
